Aarti Drugs Limited

Aarti Drugs Limited

502.80
INR
+1.55
(+0.31%)
25.06EPS
17.19P/E
39.33BMarket Cap
Jan 27Next Earn

Q3 FY2026 · Earnings Call TranscriptFebruary 4, 2026

Operator

Ladies and gentlemen, good day and welcome to Q3 and 9 Months FY26 Earnings Conference Call of Aarti Drugs Limited. As a reminder, all participants' lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Before we begin, a brief disclaimer: this call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on date of this call.

These statements are not guarantee of future performance and it may involve risks and uncertainties that are difficult to predict. I now hand over the conference to Mr.

Adhish Patil, COO and CFO from Aarti Drugs Limited. Thank you, and over to you, sir.

Adhish Patil

Thank you. Good morning to all our stakeholders.

We appreciate your participation in Aarti Drugs Q3 and 9 Months FY26 Earnings Conference Call. Joining me today are Mr.

Harshit Savla, Joint Managing Director;

Harshit Savla

Morning.

Adhish Patil

Mr. Harshit Shah, Whole-Time Director; Mr.

Vishwa Savla, Managing Director, Pinnacle Life Science; along with our Investor Relations advisor SGA. We trust that you had the opportunity to review our financial results and investor presentation for the quarter and nine months ended 31st December 2025, which have been uploaded with stock exchanges and are also available on our website.

I will begin by outlining the key operating and business highlights for the period, following which we will discuss financial performance. On the business side, it is important to note that several factors weighed on this quarter's performance.

Utilization levels remained low, impacting overall performance and operating leverage. First, weaker antibiotic demand reduced overall market pull, leading to lower capacities being utilized and creating margins pressure.

Secondly, we faced delays in shipments from China that disrupted supply chains and extended lead times, straining production schedules and added to cost pressures. Third, a one-time voluntary shutdown was undertaken in one of our plants for refurbishment ahead of the European audit, which temporarily constrained production.

Finally, the new greenfield facilities operated below optimal utilization as they are in the initial ramp-up phase. That also put pressure on profitability.

Now on the positive side, on year-on-year basis, we witnessed 7% volume growth in standalone business segment and a negative rate variance of around 5%. Export markets, especially formulations, emerged as a key growth driver, supporting overall business stability and contributing positively to margins.

Our diversified product portfolio continues to play an important role in navigating such category-specific demand fluctuations. The facility of Saykha, which operationalized in September '25, has transitioned into the scale-up phase.

It has achieved nearly 30% utilization in its first quarter of operations and we expect to ramp this up to nearly 50% by March and April 2026, and upwards to that in the following quarters. Importantly, the facility is currently meeting only 10% to 15% of our captive requirements for critical intermediates used in our anti-diabetic portfolio.

Going forward, it will significantly enhance supply reliability and reduce dependence on external sourcing, in line with our backward integration strategy. We expect to become fully self-reliant for these supplies in coming couple of quarters.

Our salicylic acid facility at Tarapur also achieved an important milestone as of now, scaling production to about 300 tons per month currently. However, the overall December '25 quarter utilization for this product was still lower than expected.

The facility has achieved improved operational stability in terms of quality parameters and solid waste management, with further improvements planned in the technology. In terms of the business segments, our formulations business showed encouraging traction during the quarter, particularly in exports market.

The increasing contribution of formulations with a higher share of exports aligns with our strategy of moving towards higher-value offerings and improving overall business quality. As new markets and products scale up, we expect formulations to play a progressively larger role in our growth trajectory.

On the regulatory front, certification and approval processes are progressing as planned. Audit observations are under review and inspections were conducted at one of our facilities as a part of ongoing regulatory initiatives, including preparations for European approvals.

This forms a part of our broader roadmap to expand presence in regulated and semi-regulated markets. After several quarters of pricing pressure, we believe the business has reached an inflection point supported by stabilizing realizations and improving volume momentum.

January month sales shows a trend which is encouraging and providing confidence in a more positive trajectory for coming quarters. Going forward, our focus remains firmly on capacity ramp-up, operational efficiency, and margin improvement while maintaining strict capital discipline and regulatory compliance.

We remain committed to executing our growth projects efficiently and building a stronger, more resilient platform for sustainable long-term growth. Now let's talk about financial performance.

At consolidated level, for Q3 FY26, revenue stood at ₹602.9 crore as compared to ₹557.1 crore in Q3 FY25, reflecting a growth of 8% Y-o-Y. EBITDA stood at ₹56.3 crores versus ₹62.3 crores in Q3 FY25, down 10% Y-o-Y basis, with EBITDA margin at 9.3%.

PAT stood at ₹40.5 crores as compared to ₹25.7 crores in Q3 FY25, up by 58% on Y-o-Y basis, translating to a PAT margin of 6.7%. For 9 Months FY26, revenue stood at ₹1,846.6 crores as compared to ₹1,713.4 crores in 9 Months FY25, reflecting a growth of 8% Y-o-Y.

EBITDA stood at ₹215 crores versus ₹196.9 crores in 9 Months FY25, up 9% Y-o-Y, with EBITDA margin at 11.6%. PAT stood at 139.7 crore as compared to 94 crores in Q3 FY25, up by 49% Y-o-Y, translating to a PAT margin of 7.6%.

With respect to standalone business, for Q3 FY26, revenue stood at ₹530 crores, contributing 88% to the consolidated revenue. Exports contributed 37% to this revenue.

Within the API business, the antibiotic therapeutic category contributed 35.1%, anti-protozoal 19.8%, anti-inflammatory 12.9%, anti-diabetic 16.6%, anti-fungal 12.2%, and the rest contributed 3.5% to the total API sales. For formulation segment, revenue from formulation stood at ₹76.6 crores in Q3 FY26, up 58% Y-o-Y.

Exports contributed 67% to this revenue. Now with this, we would open the floor for questions.

Thank you.

Operator

Thank you very much. We will now begin the question-and-answer session.

Anyone who wishes to ask a question may press star and one on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two.

Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles.

Anyone who wishes to ask a question may press star and one on their touchtone telephone. The first question is from the line of Vishal from Systematics.

Please go ahead.

Vishal Manchanda

Hi, good morning and thanks for the opportunity. My question is on the formulation business.

Just wanted to understand whether on the formulation business, the primary intention is to kind of do all the formulations of the existing APIs that we have large capacities for, or we would also do other formulations beyond our APIs that we are traditionally strong at?

Adhish Patil

Vishwa, would you like to answer this question?

Vishwa Savla

I'll answer. Currently, we're doing both.

We are working on formulations of APIs that Aarti Drugs is manufacturing in-house, but we are not restricting to that, especially on our pipeline. We are focusing more on niche categories into the oncology and cardio-diabetic range.

Wherever Aarti has an API, obviously, that is a priority, but we're not restricting only to drugs where Aarti Drugs is manufacturing the API.

Vishal Manchanda

Okay. Oncology specifically would need dedicated capacities.

Those would be separately created, right, for oncology?

Vishwa Savla

We have a within formulation, we have a dedicated oncology US FDA-approved manufacturing site.

Vishal Manchanda

Right. What is the So if you want to break up the formulation capacity between oncology and non-oncology, in terms of the investment, how would you

Vishwa Savla

Firstly, the oncology is still pre-revenue. We have not started commercial sales from the oncology side yet because the products are still in pipeline and filing stage.

The first product will be commercialized in this quarter, in Q4. In terms of the capacities, about in absolute terms, in terms of tablets, about 90% of the capacity is in the general plant.

In terms of the potential revenue over the next three years, about 40% of the revenue can be generated from oncology.

Vishal Manchanda

In terms of the investment, would that be in the same proportion, the revenue proportion or

Vishwa Savla

It would be slightly higher because on the product development part also we're investing more into the oncology. The investment would be probably about 50%, 40% to 50% on oncology.

Vishal Manchanda

We'll primarily do contract manufacturing on both the fronts, or we'll have the dossiers owned on both these categories and then partner?

Vishwa Savla

We do both. Primarily for the domestic market, we do contract manufacturing, whereas for international markets, we develop our products and dossiers and then we out-license them.

We hold the IP and we work with local partners for the marketing and distribution.

Vishal Manchanda

Okay. Just one on metformin, the backward integration capacities for the methylamines that we are creating, would that also be used for gliptins also, or that's only for metformin?

Adhish Patil

No. That is dedicated to metformin API.

Vishal Manchanda

Okay. Any sense on metformin in terms of what would be India's share in the total metformin capacities across the world?

Adhish Patil

It's we had to do the current analysis, but a couple of years back, we were roughly around 12%, 13% of the Indian capacities, but right now we have increased our capacities in last one year. With that increased capacity, probably it might have gone up upwards of 15%.

Vishal Manchanda

Okay. We have ₹180 crores sitting on CWIP.

Is that for the oncology block, or

Adhish Patil

No. It will be part would be the oncology dossier development, and part is related to big 25 tons boiler, which will be going on stream in this quarter.

It is a cogen boiler, big boiler, it will be also generating power along with the steam. It is part of our one of the greenfield projects.

Vishal Manchanda

Right. Finally, if you can quantify with the backward integration projects, the methylamine backward integration projects and all the other cost-saving investments that you've done, in what at peak utilization, if you're able to use it entirely 100%, what would be the savings that will generate in the numbers?

Adhish Patil

Yeah. I understand it's slightly difficult to give a projection because with additional capacity coming into picture, the prices will definitely move, as the margins of that product will slightly change going forward as the new entrant has come in.

It will definitely help us in improving the gross contribution further. Plus, it will also help us in improving the sales of a couple of specialty chemicals, spec chem, which has already increased in this quarter as well, and it will further increase in March quarter, and then next couple of quarters will be further ramping up the production at the Saykha facility.

Overall, what we expect is that it should give a boost of say, at least a couple of percent in gross contribution at the company level when it runs at full scale.

Vishal Manchanda

If we assume current prices and not assume any volatility in going forward, if there is an absolute number you can share if prices remain, raw material and end product prices?

Adhish Patil

It's a very rough number, very rough number. That's if it's run at full scale potential, the EBITDA can be slightly upwards of ₹50 crores.

Vishal Manchanda

Understood. Thank you very much.

Adhish Patil

Thank you.

Operator

Thank you. The next question is from the line of Resham Jain from BVD Asset Managers.

Please go ahead.

Resham Jain

Hi. Good morning.

I have a few questions. First one is if it is possible to quantify all the things which you mentioned in your opening remarks with respect to shutdown and some of the new facilities coming up, I assume there will be losses related to that.

If each of these items, if you can just quantify how much impact would be there in this quarter because of all this?

Adhish Patil

See, a couple of means both the greenfield projects put together now we don't have any issues at the Saykha facility like we had in salicylic plant, because Saykha facility, this is the first quarter of ramp-up, and we have already ramped up to 30% and it is going very smoothly as far as the ramp-up is concerned. Both this included, probably at the EBITDA level, it could have created a drag of roughly 8 or 8 8 8 8 and a half crores.

At the PBT level, probably it would be around some 14, 15 crores. That is it will change soon for the Saykha facility.

For the salicylic facility, it will change gradually in this quarter and then June quarter. As far as the other lower production capacity utilization, I don't have an exact number, but what happens what has happened, we have sold a lot from the FG stock in this particular quarter.

If you see the numbers, around ₹30 crores of sales has come from the existing stocks and not because of the fresh production. Because of that, we have estimated that roughly would have impacted around 1% in the gross margins, because when we sell from stock, the in the inventory valuation typically has 80% raw material content and 20% overhead component.

That 20% would be amounting to ₹6 crores. That has created a drag in gross margins which you see for the December quarter.

Definitely there have been multiple factors, all put together, it has created a drag in the parent company, the standalone business, which is the API and the spec chem company. Whereas the formulation department or the division has done quite well in December quarter.

The good part is in Jan, for both the segments, we are seeing good traction in the business. Hopefully this trend has already reversed and we should see some positive numbers in the March quarter.

Resham Jain

What I understood is that ₹8 crore drag at EBITDA level, which is almost 30-odd crores full-year annualized number, and could be more in the earlier quarters. What we could see next year is not just break even, but possibly as we move in the quarters, it will become positive.

The overall impact at EBITDA level will be much positive in FY27. Is that understanding correct?

Adhish Patil

Yes, that is very true.

Resham Jain

Understood. See, second question is with respect to the capex.

This year, I think you mentioned earlier last quarter that we'll have close to ₹200 crores capex this year, and that will bring an end to our overall ₹600 crore capex which we have planned earlier. What is the capex, let's say, in FY27 beyond what we have earlier planned for?

Adhish Patil

What we had planned earlier, except for one project, we are almost done with the other projects. The one project which was left out in this was expansion of metformin facility to almost around 2,500 to 3,000 tons per month.

That was our long-term strategy. However, because of some land issues, initially we ended up doing the brownfield expansion.

We already have reached around 1,450 to 1,500 tons per month. We'll be scaling it up to 1,800 tons per month in the existing facility, 1,800 to 1,900 tons per month.

Plus we are seeing some positive signs on the land side. That will also happen.

The main idea is to forward integrate in the metformin. The first step is that we are going for US FDA approval for the metformin.

We have already prepared US DMF. We are in the process of filing it, then we'll try to trigger the audit in the coming year and take it from there.

That should improve our regulated sales of metformin. Definitely it will give a very good EBITDA margin from those markets.

Plus the plan would be for the US market through Pinnacle, we might be launching ANDAs as well for the metformin tablets. Forward integration of metformin is on cards.

That was the one project which was left out from the initial plan, which we will take up in the coming couple of years. Apart from that, there are certain expansion of cardiovascular products from our existing line.

Plus we have seen some increased demand for our antifungal products, for that we're expanding capacity. Plus we are thinking in the lines of doing some level of CDMO in the chlorosulfonation chemistry where we are already strong at.

We are already doing means contract manufacturing for a few MNCs as far as a few spec chem products are concerned. We want to expand in that line as well.

Plus the methylamine chemistry, which was newly introduced through Saykha plant, we're looking at exploring the options of various derivatives which will be a part of that chemistry itself. It will help us, there will be synergies in the further expansion, so that should help us reduce cost also and plus get some value addition.

That is the overall plan for the coming years for the capex. Plus we are identifying new molecules as far as API and other spec chem segment is concerned.

That process is also on, and we will announce soon as soon as something is finalized. Having said that, I would still maintain that, around ₹150 to ₹200 crores of capex, you can expect for the next two years each, every year.

Means every year, ₹150 to ₹200 crores of capex considering the formulation, oncology expansion, and the all the ideas I've just spoke about.

Resham Jain

Understood. Very clear.

What is the current debt on books?

Adhish Patil

Current debt is roughly around ₹540 crores total debt at the consol level. In the standalone level, it would be around ₹392 crores.

In both the divisions, the debt is equally split between long-term and short-term. It's almost 50-point-something percent each.

Resham Jain

Understood. Okay.

Thank you so much. All the best

Adhish Patil

to you. Thank you.

Operator

Thank you. The next question is from the line of Dhwanil Desai from Turtle Capital.

Please go ahead.

Dhwanil Desai

Hi, good morning, Adhish. My first question is that you said that January seems promising and we are at the inflection point where the negative price variances kind of coming to an end.

Earlier we were expecting, 15% kind of a volume growth, coming through in S2. Do we see similar trend and should we expect those kind of volume and hence value growth, going forward into FY27 also?

Adhish Patil

We can expect. The main reason is the growth which we expected in FY26 hasn't come to that extent.

Which means that the growth will be pushed ahead into FY27. Probably we can expect around, 12% to 15% volume growth in FY27 with both the projects going smooth for the greenfield projects, I'm talking about.

Dhwanil Desai

Okay. Is it fair to assume that large part of volume growth will come from the new projects and existing basket of products, there, we are not expecting much of a volume growth or maybe single-digit volume growth?

Is that a fair way to look at it?

Adhish Patil

The existing product basket should give a single-digit volume growth, but the main growth driver for the volumes would be the new projects, both salicylic acid and the Saykha plant, the methylamines.

Dhwanil Desai

Fine. Second question is on the gross margin side.

Even if we adjust for the 100 basis point because of the inventory challenges, that is still below that, 36%, 37% mark that we wanted to hit. How should we look at this margin trajectory going into FY27?

Because a lot of backward integration, that will also come into play, chlorosulfonation also, will kind of pick up the specialty part of it. How should we look at that number going forward?

Adhish Patil

Yes. This particular quarter for the on a consol basis, what we can see, it is roughly around 36%, 35.9%.

The main, as I was talking about, that we have sold from inventory, so that has also impacted the gross contribution by around 1% is what we feel. That, and another thing is the export content of the standalone business in December quarter was slightly lower.

Typically the export market yields better selling prices. When the export percentage is higher, the gross margin is automatically a bit higher.

Penetrating more into export market is also one of the very critical strategy of ours, along with that pushing our existing product basket into the European markets because we are already strong in those products and we are in the process of getting European approvals for those products from our regular volume plants. From there, if we supply to Europe markets, that will definitely add to gross margin.

Backward integration, definitely yes. As I was telling that currently in December, we were only able to achieve around 12-odd percent of backward integration for the anti-diabetic, I'm talking about specifically.

That will go to, almost 90%, 100% in two, three quarters. That will also definitely help to improve the gross contribution.

Along with that, the formulation business, formulation business will impact gross contribution positively probably from second and third year. May not be in '27 immediately, but as the oncology starts flowing into the sales, then that should also definitely improve our gross contribution.

Dhwanil Desai

Okay. A follow-up on this: so on a standalone API FY27, should we expect 35%, 36% kind of a gross margin, or should we pencil in lower number?

Adhish Patil

No, I think 36% gross margin is fair to assume. It is not that tough to achieve 36% gross margin.

Dhwanil Desai

Okay. When you are saying 36% is achievable, what are the underlying assumption that we are building in that salicylic acid plant will kind of stabilize?

That's the major assumption, or the European supply picking up is also a part of it?

Adhish Patil

Overall, means one is the regulated market sales, plus the sales pickup from our E-22 plant, which is US FDA plant, and the backward integration. Means the improvement in salicylic acid will definitely give a lot of impact on the overall gross margin.

These are the main assumptions. Got it.

Last question, we said you said that we should expect ₹150 to ₹200 crore of capex for next, every year for next two years while we have just come out of a large capex cycles where plants are still scaling up, the translating into gross margin and EBITDA numbers are yet to take place. Why is it that, we don't want to first, stabilize and get to the good operational efficiency level and then do the capex rather than getting into newer projects where we'll again and continue to hit our margins?

You're absolutely correct in that analysis. There are couple of factors to that.

One is the Saykha plant, that has operationalized very smoothly. Means we have scaled up very smoothly.

We haven't seen any issues. Plus that is a captive consumption mainly, more than 50% is captive consumption from that plant.

Scaling up of that project will happen very quickly. Means so we are talking more from 24 months, and this Saykha results will start coming in six months itself.

We'll know within six months, we'll come to know whether one of the greenfield capex is fully operationalized or not. That will give us one comforting factor after six months.

Salicylic acid, we are almost at the means towards the end of improvement. One more thing, that 1 ₹150 to ₹200 crores, a part of that will also go for oncology dossier development.

That is also important because we have already oncology, means approved formulations plant, US FDA-approved plant in Baddi. We want to capitalize on that.

Plus we got European approvals for our OSD facility in Baddi, we also want to capitalize on that by having more dossiers on regular therapies for formulation. Plus this will also include the maintenance capex plus the incremental expansion what we do, brownfield expansion.

That will also be the part of this. Plus we are doing a bit of capex both in that solar power plant also and some energy-related improvements what we want to do.

That will also be taken care of in this capex. Got it.

Very clear. Thanks and wish you all the best, Adhish.

Thank you.

Operator

Thank you. The next question is from the line of Yash Doshi from Unifi Capital Private Limited.

Please go ahead. Hello.

Yash Doshi

Thank you. Am I audible?

Adhish Patil

Yes.

Yash Doshi

Yeah. In the salicylic acid plant, if I remember last quarter you said that we break even around 800 metric tons per month.

You also talked about Chinese dumping. Have the realizations stabilized or they are still the dumping is still on and the realizations have come down?

Adhish Patil

Harshit bhai, can you answer the salicylic selling prices trend?

Harshit Savla

Yeah. Chinese dumping is still on.

Due to dollar in dollar rate going up, we are getting little better realization than last quarter. We are also trying to apply anti-dumping duty from beginning of next year against Chinese imports.

Which will take about six to eight months, nine months, whatever time, after April, you know. Because we are not eligible as of now, maybe from April onwards, we are eligible to apply for anti-dumping duty also.

Let's hope that, we In in operational side, we are trying we are improving our overall efficiency so that, we come out of this and break even for next year.

Yash Doshi

Just

Adhish Patil

on

Yash Doshi

Yeah. Just for confirmation, the salicylic acid plant and Saykha plant both combined reported 8.5 crores of EBITDA loss this quarter, or it's a single plant 8.5 crore loss?

Adhish Patil

It's a combined. Combined.

Yash Doshi

Okay. Regarding next year, if you look at the EBITDA margins, this quarter because of multiple headwinds, we reported 9%.

For next year steady state, what EBITDA margin we will be around?

Adhish Patil

See, first of all, initially, we would like to hit the target of 12% to 13% because right now it was struck down well below that. Right now it is around 9.3%, but just previous quarter in September, it was around 12.9%.

First we'll come there, 12% to 13%, and then from there, the ideal steady-state margins when everything starts going smoothly should be somewhere in 14% to 15% range.

Yash Doshi

Okay. On the Saykha plant, what we are targeting next year?

This year we are targeting 50%, I think Q4 exit rate will be around 50%. Next year, what is our target?

Adhish Patil

Yeah. Saykha first quarter first quarter we were able we were able to do around 30% utilization.

Immediately in this current quarter, March quarter, we are planning to ramp up to around 50% utilization, and then in the subsequent quarter, we are planning 75% utilization of the facility. The ramp-up should be pretty fast.

Within hopefully within 12 months, we should be almost there till 80%, 90%.

Yash Doshi

Okay. Same for the salicylic acid plant next year?

We are targeting around 800, 1,000 metric tons per month? Yeah.

Adhish Patil

Yes. Salicylic acid, we are going slightly slowly.

There have been a lot of changes. What happened, the story is like this.

We started the plant almost in April '24 and in Jan '25, we saw around one year back, we saw there were drastic changes in the specifications of salicylic acid since the time we commissioned the plant. We had to take care of that quality parameters as well, we had to tweak our processes a little bit.

Currently, what we are observing is that in I'm talking about the industry and the competitors, the process the physical chemistry of the organic chemistry has remained same, but the physical chemistry is slightly the new technology is coming in for salicylic acid. We are also exploring that part to adopt that technology in our plants so that and that is important for us to be competitive going future in going forward.

That is the only reason why salicylic acid, I'm saying still we are going a bit slowly, but within 12 months, probably we should try to hit that 1,000 tons per month mark. That should be our target.

We are also cautious about the new technologies which are coming in, which haven't been adopted yet, but they are in the discussion of getting adopted at plant scale. That also we are exploring.

Yash Doshi

Okay. Understood.

That's from my side. All the best.

Adhish Patil

Thank you.

Operator

Thank you. The next question is from the line of Aditya from Sowiilo Investments.

Please go ahead. Hi.

Aditya Ravindran

Thanks for opportunity. I just wanted to understand the API pricing as such.

A couple of quarters ago, there were discussions that could be the bottom but looks like dumping is going on and prices also there has been pressure. What kind of trajectory are we seeing especially for API?

Adhish Patil

Yeah. See, what we have observed is that overall rate negative rate variance in December quarter with respect to September '25, that is quarter-on-quarter, it is roughly around 2% to 2.5%.

Having said that, it is mainly the entire reason for that is the antibiotic segment. The other segments, frankly speaking, in some of the other segments, we have seen positive growth as well in the prices.

It is product-specific. We will still maintain the stance that the prices have stabilized from September onwards, just product-specific variations are there a little bit.

More or less, the prices have already stabilized. We don't see any reduction of prices from this point.

Aditya Ravindran

Okay. Just recent I'm just trying to understand whether that affects us or no.

Adhish Patil

Just

Aditya Ravindran

recent, we had the government establish MIP for penicillin, right? Would that have any kind of bearing in terms of our input cost?

Adhish Patil

Not now. Means right now we don't deal in that segment.

The concept of MIP we are trying to explore that in few of the cases which will help us benefit to get better realizations for our products which we sell as import substitute.

Aditya Ravindran

Understood. Okay.

Thank you. That's it from my side.

Adhish Patil

Thank you.

Operator

Thank you. The next question is from the line of Sashi Ranjan from Sashi Ranjan Hospitality Private Limited.

Please go ahead.

Sashi Ranjan

Good morning. Thank you for the opportunity.

I would like to understand the molecule that was banned on 31st December 2025, talking about nimesulide. How it's going to impact our up to 100 mg, how it's going to impact our revenue in future?

Adhish Patil

Regarding nimesulide?

Sashi Ranjan

Yes, sir.

Adhish Patil

Okay. Harshit bhai, can you

Harshit Savla

Basically the recent ban was for nimesulide more than 100 mg, and typically in India, this product we have all formulations where we are selling is less than 100 mg. We are not affected as far as demand is concerned.

These are for very high dosages which only two or three, four companies were doing it actually. All our customer base are within the range and so there is no problem with the demand for that molecule as of now.

Sashi Ranjan

Just a clarification on that, can we quantify the revenue that we get from nimesulide from the below 100 mg formulations?

Adhish Patil

Most of our sales in nimesulide is less than 100 mg, yeah.

Sashi Ranjan

No, I'm asking about the revenue, sir, that we get from nimesulide.

Adhish Patil

We don't have that number right now. Probably we can get it get back to you later on.

Sashi Ranjan

Thank you, sir. My next question, if you may allow, what is the capacity utilization currently in API and FDS?

Is it again 30% and 50% which you answered earlier?

Adhish Patil

What I was talking about that in the opening remarks that this particular quarter, even when we compare to our capacity utilization for the first two quarters of this current year, that is the H1 FY26, we were almost down by 4% to 5% even from what we achieved in the first two quarters. We also highlighted the reasons why it happened.

Most of the reasons are behind us. Going forward, we don't see such disruptions for coming quarters at least.

Sashi Ranjan

Coming to the last question, what is the gross margin and the revenue that we are getting from CDMO? Are we going to use the backward integrated products in the CDMO products that we are currently operating?

No, backward integrate

Adhish Patil

so whatever products we are doing in spec chem, means you can call it CDMO or CMO, they are chlorosulfonation chemistry. We are already backward integrated in chlorosulfonation.

These are all derivatives of that chlorosulfonation chemistry. We are that way backward integrated already.

I cannot quantify in terms of percentage because right now it is not that big for us. That is the reason why we still club it under spec chem segment as of now.

Sashi Ranjan

Okay. Now coming to the last question, the European approval that we got from product in Baddi, is it related to oncology or any other molecule?

Adhish Patil

That is OSD, oral Vishwa, can you would you want to answer that?

Rishabh Mishra

It's for the general tablet and capsule facility, as well as the oncology facility. It was an joint inspection for both the facilities and now we have EU GMP for both the oncology as well as the general oral solid site.

Sashi Ranjan

Thank you so much, sir. That's all from my side.

I'll get back in the queue.

Adhish Patil

Thank you.

Rishabh Mishra

Thank you.

Operator

Thank you. The next question is from the line of Vishal from Systematics.

Please go ahead.

Vishal Manchanda

Hi. Thanks for the opportunity.

Can you share what would be the total investment including the dossier development cost we'll be making in the oncology business?

Adhish Patil

Vishwa, would

Rishabh Mishra

you The facility capex in both phases, what we initially did and we have a brownfield expansion going on, would be about ₹50 crores. In terms of the product development and regulatory related, it would be about again ₹50 to ₹60 crores every year for the next three years.

That is what we're spending on the product development, yeah. Okay.

Vishal Manchanda

Broadly ₹200 crores, right?

Rishabh Mishra

Correct. Yeah, ₹200 crores spread over time, yeah, including capex as well as product development and regulatory.

Vishal Manchanda

Okay. Can we expect an asset turn of 1.5 here?

Rishabh Mishra

Yes, we can expect about 1.5 to 1.75 peak capacity.

Vishal Manchanda

Okay. Do we already have partners for the dossiers that we are filing?

Rishabh Mishra

Yes, usually we in most of the territories, we are having B2B partners before we file. Okay.

Vishal Manchanda

Our capacity roughly would be 300 million pills for oncology?

Rishabh Mishra

Yes, that's right, 300 million.

Vishal Manchanda

Just one on salicylic acid: if you could give some sense on why we kind of went to why we chose salicylic as a import substitute option while there were so many, you could have also chosen a backward integration project for metformin, and why did we go for salicylic acid?

Adhish Patil

Yeah. We studied pricing trend of salicylic acid for the five to six years when we selected that product.

At that time, no one was manufacturing that product and the technology what we had developed, it showed very high profit margin. Means IRRs of the project were upwards of 20% for that product.

What happened was when we entered the market, that is the time when China started crashing the prices, probably because they were fearful that a new entrant will come. If they keep the prices to rock bottom for the initial period, that will discourage us from going ahead with salicylic.

We foresee that as a you can say entry barrier or a temporary entry barrier what they are trying to create. Fortunately, this also becomes the case of anti-dumping because they crashed the prices when the Indian manufacturer came in.

If we get that benefit even for the first few years, we are sure that we will turn it around because the same thing had happened for metro and ciprofloxacin also in past. We had got anti-dumping duties for four, five years, and by the next round when it came, we were so profitable that we did not qualify for anti-dumping duty.

We feel this will turn around. The thing is salicylic acid also opens up a big opportunity for us to enter into cosmetic and healthcare line of business and not just restrict ourselves to API.

That is one another advantage what we have through salicylic acid. It is a base product used to manufacture salicylates, which goes in flavor and fragrances industry as well.

Vishal Manchanda

We'll do downstream products from this?

Adhish Patil

The thing is right now the situation is such that we are compelled to do. We have already developed technology for that, we have done piloting also for the downstream products.

We are coming up with salicylate block as well very recently in a quarter or two. Let's see how that picks up.

Vishal Manchanda

Sir, have we made an application for anti-dumping duty?

Adhish Patil

As Harit bhai was pointing out that earlier we did not qualify, but now, I think by April or so, right Harit bhai, we'll be filing for the Yes. By April, we'll be filing the application, probably.

April onwards, this first quarter and not first quarter, [unclear]. First quarter.

Vishal Manchanda

Sir. Thank you very much.

Adhish Patil

Thank you.

Operator

Thank you. Ladies and gentlemen, due to time constraints, that was the last question for today.

I now hand over the conference to management for closing comments.

Adhish Patil

Thank you. Strategic investments and initiatives we have implemented over past year is beginning to align, setting the stage for new phase of growth for Aarti Drugs.

We anticipate a more pronounced impact on our financial performance in the upcoming quarters as capacity utilization scales up and our enhanced product mix begins to deliver higher profitability. We appreciate your continued support and trust in Aarti Drugs.

Should you have any further questions, please reach out to SGA, our Investor Relations advisors. Thank you, and have a nice day.

Operator

Thank you. On behalf of Aarti Drugs Limited, that concludes this conference.

Thank you for joining us, and you may now disconnect your lines. Thank you.